Granalix BioTechnologies

Granalix BioTechnologies was established to develop innovative, science-based formulations of natural antioxidants that can be used for the prevention and treatment of neurodegenerative conditions. The company's first product, GranaGard, is a submicron self-emulsion formulation of pomegranate seed oil, which contains high concentrations of punicic acid (PA), one of the strongest natural antioxidants. In the GranaGard formulation, PA has been shown to convert in vivo into conjugated linoleic acid, an established neuroprotector and mitochondrial activity modulator. GranaGard was shown to delay disease onset in a mouse model of genetic prion disease, which presents neurodegenerative features reminiscent of Alzheimer's disease, as well as to reduce disease burden in a mouse model of multiple sclerosis. All components of GranaGard are generally regarded as safe by the FDA.

Granalix BioTechnologies operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development, with core technologies in Biologicals, Herbals. Target customers: Healthcare & Life Sciences, Healthcare, Patients, Consumers, Demographics & Family, Seniors.

Granalix BioTechnologies is based in Yad Harutsim Street 6, Jerusalem, Israel, Jerusalem District.